Italia markets closed

JNJ Jan 2025 145.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
5,83-0,67 (-10,31%)
Alla chiusura: 03:29PM EDT
Schermo intero
Chiusura precedente6,50
Aperto6,00
Denaro5,50
Domanda5,95
Prezzo d'esercizio145,00
Scadenza2025-01-17
Min-Max giorno5,83 - 6,00
Contratto - Min-MaxN/D
Volume5
Open Interest3,04k
  • GlobeNewswire

    Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

    According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA